Table 3.
PRO clinical trials characteristics
| Trial characteristics | Number of trials, (%) |
|---|---|
| Trial phase | |
| I | 0 |
| I/II | 1 (1.4) |
| II | 1 (1.4) |
| III | 24 (34) |
| Other | 3 (5.7) |
| Not specified | 40 (57) |
| Leading study centre | |
| UK | 62 (89) |
| International | 7 (11) |
| Trial design | |
| International multicentre study | 21(30) |
| PRO outcome | |
| Primary outcome | 17 (24) |
| Secondary outcome | 35 (50) |
| Both | 11 (15) |
| PRO measures used | |
| SF-36 | 17 (24) |
| EQ-5D | 12 (17) |
| HADS | 9 (13) |
| VAS | 9 (13) |
| EORTC QLQ-C30 | 3 (4) |
| Other | 70a |
aNumber of different PRO measures identified – eCase studies characteristics